Michael Barbella, Managing Editor09.16.22
Veracyte Inc. has appointed Eliav Barr, M.D., to its Board of Directors.
“We are thrilled to welcome Eliav Barr to our board,” CEO Marc Stapley said. “Dr. Barr has exceptional global biopharmaceutical industry experience, which will be key to helping us achieve our ambition of improving outcomes for patients all over the world. We are also eager to benefit from his expertise in our efforts to further expand our biopharmaceutical partnerships by leveraging our data assets and multi-omics capabilities, particularly in immuno-oncology.”
Barr has built his career at Merck Research Laboratories (MRL), a division of Merck & Co. Inc., where he has served as head of Global Clinical Development and chief medical officer since April 2022. In this role, he oversees development programs for pipeline and in-line products in the cardiovascular, diabetes/endocrine/metabolism, immunology, neurology, oncology, psychiatry, respiratory, and vaccines/infectious diseases therapeutic areas. He also chairs the Late Development Review Committee, the governance committee that oversees such pipeline.
Barr has held numerous leadership positions within MRL since joining the company in 1995, including serving as senior vice president, Global Medical and Scientific Affairs from 2018 to 2022. Notably, he led the development of Merck’s human papillomavirus (HPV) vaccines, which have become key tools in the global effort to reduce the burden of certain cancers and diseases caused by HPV. Prior to joining Merck, Barr pursued post-doctoral training at the University of Michigan and was on faculty at the University of Chicago.
Barr earned his Doctor of Medicine degree from Jefferson Medical College of Thomas Jefferson University and completed an internal medicine residency and cardiology fellowship at Johns Hopkins.
“Veracyte provides high-value diagnostic tests that help physicians make more informed diagnostic and treatment decisions for their patients,” said Barr. “I am excited to join Veracyte’s board of directors and help guide the company as it executes on its strategic global vision.”
Veracyte is a global diagnostics company that improves patient care by answering important clinical questions to inform diagnosis and treatment decisions. Its menu of advanced diagnostic tests help patients avoid risky, costly procedures and interventions, and reduce time to appropriate treatment. Veracyte is based in South San Francisco.
“We are thrilled to welcome Eliav Barr to our board,” CEO Marc Stapley said. “Dr. Barr has exceptional global biopharmaceutical industry experience, which will be key to helping us achieve our ambition of improving outcomes for patients all over the world. We are also eager to benefit from his expertise in our efforts to further expand our biopharmaceutical partnerships by leveraging our data assets and multi-omics capabilities, particularly in immuno-oncology.”
Barr has built his career at Merck Research Laboratories (MRL), a division of Merck & Co. Inc., where he has served as head of Global Clinical Development and chief medical officer since April 2022. In this role, he oversees development programs for pipeline and in-line products in the cardiovascular, diabetes/endocrine/metabolism, immunology, neurology, oncology, psychiatry, respiratory, and vaccines/infectious diseases therapeutic areas. He also chairs the Late Development Review Committee, the governance committee that oversees such pipeline.
Barr has held numerous leadership positions within MRL since joining the company in 1995, including serving as senior vice president, Global Medical and Scientific Affairs from 2018 to 2022. Notably, he led the development of Merck’s human papillomavirus (HPV) vaccines, which have become key tools in the global effort to reduce the burden of certain cancers and diseases caused by HPV. Prior to joining Merck, Barr pursued post-doctoral training at the University of Michigan and was on faculty at the University of Chicago.
Barr earned his Doctor of Medicine degree from Jefferson Medical College of Thomas Jefferson University and completed an internal medicine residency and cardiology fellowship at Johns Hopkins.
“Veracyte provides high-value diagnostic tests that help physicians make more informed diagnostic and treatment decisions for their patients,” said Barr. “I am excited to join Veracyte’s board of directors and help guide the company as it executes on its strategic global vision.”
Veracyte is a global diagnostics company that improves patient care by answering important clinical questions to inform diagnosis and treatment decisions. Its menu of advanced diagnostic tests help patients avoid risky, costly procedures and interventions, and reduce time to appropriate treatment. Veracyte is based in South San Francisco.